Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-11

Study Completion Date

2025-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.), which risks distorting the results; this is estimated to affect 0.5 to 2.5% of samples.

This is particularly the case for anti-Xa activity, a critical test used to monitor anticoagulant treatments.

To date, the HUS Hematology Laboratory does not have or is aware of any alternative method to overcome this interference, and is unable to perform anti-Xa activity when the sample has excessive lipemia. This study will evaluate, on samples from routine care artificially overloaded with lipids, the effectiveness of a high-speed centrifugation process (10,800g for 10 minutes).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.

NCT02579941

Hyperfibrinolysis

COMPLETED NA

Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery

NCT00778492

Bleeding

UNKNOWN

Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery

NCT05783895

Heparin-induced Thrombocytopenia

UNKNOWN

Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty

NCT04691362

Hemorrhage Postoperative Total Blood Loss Arthroplasty Complications

COMPLETED PHASE4

Tranexamic Acid (TXA) in Hip Arthroscopy

NCT05710146

Hip Pain Chronic Hip Impingement Syndrome Hip Injuries +2 more

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertriglyceridemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥ 18 years)
* Patient anticoagulated with an anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban)
* Sample sent to the HUS Hematology Laboratory and analyzed for measurement of the anti-Xa activity of an anticoagulant as part of routine care